Latest Medical Technology News

Page 2 of 23
Clever Culture Systems has started FY27 with three APAS Independence sales to Novo Nordisk and AstraZeneca, while targeting eight first-half sales and evaluations. The sales momentum comes with $1.6 million of unsecured loans due in December and a proposed extension still to be secured.
Victor Sage
Victor Sage
30 Oct 2026
Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.
Ada Torres
Ada Torres
29 Oct 2026
Control Bionics has begun converting its expanded product and regulatory pipeline into revenue, while a completed $9.75 million capital raising gives the company a larger cash buffer. The next test is whether partner-led sales and NeuroStrip trial conversions can reduce its cash burn as planned.
Victor Sage
Victor Sage
29 Oct 2026
4DMedical reported a record first quarter, with scan volumes up 61% to 119,672 and unaudited operating revenue rising 66% to $2.3 million. New contracts across the US, Germany and Australia broaden the commercial story, while $242.8 million in cash gives the company room to keep investing.
Victor Sage
Victor Sage
28 Oct 2026
Singular Health has moved closer to a proposed A$3.5 million Florida Medicaid imaging repository while deploying 1,000 physician licences through its largest customer network. The September quarter also exposed the execution risks ahead, with the Florida MOU still subject to definitive agreements and the PNS contract due for renewal by year-end.
Victor Sage
Victor Sage
27 Oct 2026
Nova Eye Medical delivered 30% year-on-year sales growth in the September quarter, alongside positive operating cash flow and EBITDA. The company confirmed FY27 guidance, but is still seeking to replace a related-party funding facility carrying 15% interest.
Victor Sage
Victor Sage
27 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
Victor Sage
Victor Sage
26 Oct 2026
Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.
Victor Sage
Victor Sage
26 Oct 2026
Proteomics International will take Promarker D and Promarker Eso nationwide through Healius from 26 October, extending its first commercial release beyond Western Australia and the Northern Territory. The tests will initially be offered privately at $495 and $997, while revenue remains too uncertain to forecast.
Victor Sage
Victor Sage
23 Oct 2026
Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.
Ada Torres
Ada Torres
22 Oct 2026
CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
Victor Sage
21 Oct 2026

Browse the archive

Full archive